Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus
patients when treated with long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonists …

Objective. Data from randomized clinical trials with metabolic outcomes can be used to
address concerns about potential issues of cardiovascular safety for newer drugs for type 2 …

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …

Type 2 diabetes (T2D) is associated with increased cardiovascular disease and mortality.
Most diabetes treatments have not proven to reduce this risk and may be associated with …

Abstract Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family,
and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic …

Purpose The aim of this study is to examine the cardioprotective properties of Glucagon-like
peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four …

In recent years, we have witnessed the many beneficial effects of glucagon‐like peptide
(GLP)‐1 receptor agonists, including the reduction in cardiovascular risk in patients with type …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that has undergone a revolutionary
turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone secreted by the small intestine in
response to nutrient ingestion. It has wide‐ranging effects on glucose metabolism, including …